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Does medical technology originating in countries close to the technology frontier have a sig-
niﬁcant impact on health outcomes in countries distant from this frontier? This paper considers
a framework where lagging countries may beneﬁt from medical technology (a result of research
and development by countries close to the frontier) that is embodied in medical imports or dif-
fuses in the form of ideas. Using a novel dataset from a cross-section of 73 technology-importing
countries, we show that medical technology diﬀusion is an important contributor to improved
health status, as measured by life expectancy and mortality rates.
Keywords: Health status, medical technology diﬀusion, R&D spillovers.
JEL Classiﬁcation: O30, O40
∗Special thanks go to Ben Bridgman, Josh Lerner, Francesco Ricci, and Fidel Perez-Sebastian for detailed com-
ments and suggestions. We also thank Shankha Chakraborty, Peter Howitt, Peter Thompson and participants of
seminars at the 2004 Midwest Macroeconomics Meetings at Iowa State University, CRETE 2004 at Syros Greece, the
2004 European Economic Association meetings in Madrid, Lousiana State University, the University of Cyprus, and
the NEUDC 2004 Conference in Montreal for useful comments.International Medical R&D Spillovers 1
1I n t r o d u c t i o n
One of the most fundamental aspects of economic development and a nation’s welfare is the pop-
ulation’s level of health as manifested by a variety of indicators, such as life expectancy at birth
or mortality rates. Along with the level of education, health is a basic component of a nation’s
human capital. Understanding the main forces that have led to improvements in life expectancy
is one of the fundamental questions of economic policy. A number of commentators have pointed
out that improvements in life expectancy over the past two centuries have been driven primarily by
two forces: general increases in the level of per capita income and the diﬀusion of medical technol-
ogy from countries at the core of medical innovation to the periphery. While income is primarily
thought to be responsible for health improvements in the 19th century, the diﬀusion of medical
technology is thought to have been responsible during the 20th century, especially the latter half of
the century. For instance, Kremer (2002, p. 67) emphasizes the importance of modern medical tech-
nologies in allowing “... tremendous improvements in health even at low income levels.”1 Moreover,
commentators have pointed out that while income inequality has tended to increase throughout
the past two centuries, inequality in life expectancy has tended to decline, especially during the
past ﬁfty years or so. Bourguignon and Morrisson (2002, p. 741) report that “... unlike income,
world inequality in life expectancy fell considerably after 1930, as improvement in world mean
life expectancy accelerated.”2 Becker, Philipson and Soares (2003, p.1) argue that “...in the last 50
years, countries starting with modest longevity levels experienced life expectancy gains signiﬁcantly
larger than countries starting with high longevity levels.” Fogel (1994, p. 388) points to a potential
explanation for the acceleration of life expectancy improvements in “... the huge social investments
made between 1870 and 1930, whose payoﬀs were not counted as part of national income during
the 1920’s and 1930’s even though they produced a large stream of beneﬁts during these decades”
and adds that he “... refer[s], of course, to the social investment in biomedical research.”
The general trends in life expectancy over the past two centuries are shown in Table 1. The
table shows the inexorable increase, across the globe, in life expectancy since 1820, punctuated by
1He oﬀers an illuminating observation on the importance of technology diﬀu s i o ni nb o o s t i n gl i f ee x p e c t a n c yi nt h e
case of Vietnam where at the end of the 20th century life expectancy stood at “... 69 years despite a per capita income
that according to oﬃcial statistics is less than one-tenth that of the United States in 1900, which had a 47-year life
expectancy.”
2In related work, Jamison, Sandbu, and Wang (2001) document the importance of diﬀerent rates of technological
progress across countries for the declining cross-country variation in infant mortality rates.International Medical R&D Spillovers 2
Table 1: Life Expectancy at Birth: 1820-2000
Region 1820 1890 1910 1929 1950 1960 1970 1980 1990 2000
Sub Saharan Afr 25.3 25.6 26.7 30.6 36.3 40.2 44.2 47.6 50.0 46.5
Latin America 29.1 33.2 37.2 41.8 51.7 56.4 60.5 64.6 67.9 70.4
East Asia 25.1 25.2 26.2 30.2 43.5 39.2 59.1 64.4 67.3 69.1
South Asia 23.0 23.0 23.0 27.0 40.6 43.9 48.9 53.7 58.7 62.7
High Income 34.6 42.5 48.7 56.8 65.8 69.6 71.4 74.0 76.1 78.0
World 26.5 29.6 32.4 37.6 48.8 50.2 58.6 62.6 65.3 66.5
Notes: Each regional average is population weighted. Country data for 1820-1950 are from Bourguignon and Mo-
rrisson (2002) and for 1960-2000 from the World Development Indicators (2002). South Asia includes Bangladesh,
India and Pakistan. High Income includes Australia, Austria, Belgium, Canada, Czechoslovakia, Denmark, Finl-
and, France, Germany, Hungary, Ireland, Italy, Japan, Luxembourg, Netherlands, New Zealand, Norway, Portugal,
Spain, Sweden, United Kingdom and the United States. The other three regions are as deﬁn e db yt h eW o r l dB a n k .
two periods of falling life expectancy: East Asia during the 1950s and Sub-Saharan Africa during
t h el a s td e c a d eo ft h e2 0 th century.3 What is evident is that throughout the 19th century, except
for Latin America,4 the countries of the periphery experienced hardly any improvements in life
expectancy, while the high income economies experienced a 40 percent increase from 35 years in
1820 to 49 in 1910. More importantly, the life expectancy gap between the high-income economies
and the rest of the world widened during the 19th century: the gap between Sub-Saharan Africa
and Asia, on the one hand, and the high-income economies increased from about 9 years in 1820 to
more than 20 years in 1910. The ﬁr s th a l fo ft h e2 0 th century witnessed the ﬁrst important increases
in life expectancy in the developing world: between 1910 and 1950 life expectancy increased by 36
percent in Sub-Saharan Africa, by 39 percent in Latin America, by 66 percent in East Asia and
by 76 percent in South Asia. Life expectancy improvements accelerated in the developing world
during the second half of the 20th century: over the 1950-2000 period life expectancy increased by
3.7 years per decade in Latin America, by 6 years in East Asia, by 4.5 in South Asia, and by 3.4
years in Sub-Saharan Africa (until 1990 and the reversal during 1990-2000.) The corresponding
3The drop in life expectancy in East Asia in the 1950s is wholly explained by the reduction in China’s life
expectancy from 44 years in 1950 to 36 years in 1960. This coincided with the policies adopted by the victorious
Chinese Communist Party following the civil war of the late 1940s culminating in the Great Leap Forward and
t h eg r e a tf a m i n eo ft h el a t e1 9 5 0 s . S u b -Saharan’s recent reduction in life expectancy is due to the rapid spread of
HIV/AIDS across the continent.
4Our Latin America grouping in Table 1 includes what were some of the wealthiest countries of the 19th century
(e.g. Argentina and Chile). Bourguignon and Morrisson (2002) chose to include these countries in a separate category:
Western Europe and European oﬀshoots. In Table 1 we adopt the World Bank classiﬁcation of country groupings to
reﬂect our empirical emphasis on the recent experience of various countries.International Medical R&D Spillovers 3
ﬁgure for the high-income economies was 2.5 years per decade.5
In this paper, we argue that research and development (R&D)-induced advances in medical
technology systematically diﬀuse across the world and are, thus, partly responsible for the decline
in life expectancy inequality discussed above. We focus on the diﬀusion of medical technology
both in terms of its embodiment in medicines and medical equipment that are exported from the
innovating countries to the rest of the world (and thus can be termed as the ‘indirect’ beneﬁts
of R&D-induced medical technology) and the diﬀusion of ideas arising from R&D in advanced
countries (and can, thus, be termed as the ‘direct spillover’ beneﬁts of medical technology.) The
importance of the diﬀusion of medical technology in improving health outcomes across the world is
well known to social scientists and epidemiologists but has received little attention by economists.
In a fascinating book, Rocco (2004) traces the importance of medical discoveries and their
diﬀusion across the globe in controlling the spread of malaria and, thus, facilitating major global
economic events.6 The property of the bark of the cinchona tree, native to the Peruvian Andes, to
cure the symptoms of malaria was ﬁrst noted by Jesuit priests (sent to set up missions in South
America) in the College of San Pablo in Lima in the ﬁr s th a l fo ft h e1 7 th century. Knowledge of
the miraculous qualities of the cinchona bark spread to Europe, with Peru serving as a center for
the distribution and trade in the bark. By the late 18th century, trade in cinchona bark accounted
for a large part of transatlantic trade and “oﬃcial imports of cinchona ... amounted to a total that
was valued at more than ten million reales ... three times that of exotic hardwoods from the Indies,
and ... nearly 2 per cent of all imports from South America” (p. 83). It was not until the last
decade of the 19th century that the role played by the anopheles mosquito in the transmission of
the Plasmodium malaria parasites to human beings became known through the research of Major
Ronald Ross in India. Soon knowledge of his breakthrough was transmitted to England and the
rest of the scientiﬁc community through his correspondence with Patrick Manson, a specialist in
tropical medicine. Both trade in commodities and ideas played the decisive part in combating the
devastating eﬀects of this disease.
Our paper concentrates on the channels by which medical technology diﬀuses from a handful
5Bourguignon and Morrisson (2002) calculate that the Theil index of life expectancy inequality rose throughout
the 19th century to reach 0.045 by 1910 and then declined through most of the 20th century to reach 0.013 by 1992.
6These included, among others: (a) the opening up of west and central Africa to exploration and eventual colo-
nization; (b) the unsuccessful attempt by the French to construct the Panama canal, due to their inability to control
malaria, and the success of American engineers in this endeavor, after controlling the spread of the disease; and (c)
the opening up of the American west.International Medical R&D Spillovers 4
of countries to the rest of the world and its impact on health. We argue that countries beneﬁt
from foreign medical R&D even in the absence of domestic medical R&D, and the extent of these
beneﬁcial eﬀects is transmitted through two channels. First, imports of medical goods. Similar
to Caselli and Wilson (2003) and as shown by Eaton and Kortum (2001) for capital equipment,
we consider that production of goods embodying medical technology is concentrated in a small
number of R&D-intensive countries while the rest of the world typically imports these goods; thus,
these imports capture adequately the impact of new embodied medical technology on the overall
health level in these countries. Second, R&D carried out in advanced economies may also have
spillover eﬀects in terms of generating knowledge and ideas that can be used (as in the case of
capital goods) by producers other than those carrying out the R&D. These producers may be
located within or across the country’s borders. This should be particularly important in the case of
providers of medical services (say physicians) who are likely to improve their practice by utilizing
ideas developed in frontier countries.
A number of studies have investigated the diﬀusion of technology embodied in capital goods
(and used by the manufacturing sector) from advanced R&D performing economies to the rest of the
world. Spending on R&D has been shown to boost productivity and growth not only in economies
carrying out R&D but also other economies beneﬁtting from international R&D spillovers.7 No
study has considered the global diﬀusion of medical technology and the potential welfare-enhancing
beneﬁts of medical R&D by technologically-advanced countries in terms of health improvements in
less advanced economies. This should stand as a surprise because the pharmaceutical industry is
the single most R&D-intensive industry, no less so than capital goods production.8 In this paper,
we propose that, similar to capital goods in manufacturing, medical goods such us pharmaceuticals
(e.g. vaccines and antibiotics) or medical equipment (e.g. surgical instruments), embody R&D
induced technology. Moreover, R&D in the pharmaceutical industry is highly concentrated in
a small group of ten countries which are also the main exporters of these goods. In sum, it is
reasonable to expect that advances in medical technology occurring in a small group of developed
economies diﬀuse to the rest of the world either embodied in medical exports or “disembodied” in
the form of ﬂow of ideas and may, potentially, have a signiﬁcant impact on health status in the rest
7A lengthy literature documents the importance of international R&D spillovers for capital goods; see Coe and
Helpman (1995), Coe, Helpman, and Hoﬀmaister (1997), and Keller (2002).
8Lichtenberg and Virabhak (2002) also emphasize that pharmaceuticals are more R&D intensive than capital
equipment imports.International Medical R&D Spillovers 5
of the world.
In what follows, we oﬀer a skeletal model of the endogenous determination of health status that
emphasizes the role of medical imports and foreign technology spillovers. Subsequently we assess
empirically the impact of technology diﬀusion in determining health status. Our baseline model
links health outcomes to medical technology ﬂows embodied in imports or directly via ideas. We
augment our baseline model to test the robustness of the underlying relationship. For example,
it is well known that the richer an individual the greater the health inputs a person can aﬀord
and healthier individuals are more productive. Therefore we would expect health status and the
level of per capita income to be closely interconnected (indeed the correlation coeﬃcient between
per capita income and life expectancy in our data is 0.77). Our empirical strategy takes account
of this interconnection, ﬁrst, by including (the exogenous component of) income per capita as
a determinant of life expectancy and, second, by including a variety of health inputs through
which income per capita might indirectly aﬀect life expectancy (e.g. calorie intake, the number
of physicians, female illiteracy rates, access to safe water, sanitation, and the number of hospital
beds). In addition to these, we attempt to control for geographic and climatic conditions by
including a measure of proximity to the tropics. This measure is closely related to the exogenous
arrival of diseases in the theoretical framework of the next section. Finally, we perform a number
of robustness checks and show that our results regarding the importance of technology ﬂows for
health status are robust. For example, we demonstrate that our estimates do not merely capture
a broad “trade openness” eﬀect, but instead depend on the degree to which a given import type
embodies R&D-induced technology (see section 4 for details).
The remainder of the paper is organized as follows. Section 2 describes a rudimentary model
that links medical imports and endogenous life expectancy and serves to motivate our empirical
analysis. Section 3 discusses our novel dataset on medical imports and takes a ﬁrst look at the
correlations between medical imports and alternative indicators of health. Section 4 presents our
empirical analysis and reports our main results. Section 5 concludes.
2 A model of health status and medical imports
In this section we provide a theoretical justiﬁcation for our main hypothesis relating medical im-
ports and health status. We construct a simple model in which the medical imports-health statusInternational Medical R&D Spillovers 6











relationship emerges as an equilibrium outcome of optimal decisions by a representative agent. A
novel feature of the model is that health status is determined endogenously, in contrast to most
existing models where it is exogenously given.9
The motivation for endogenizing health status is pioneering work by Fogel (1994) and Licht-
enberg and Virabhak (2002) showing that the decision to consume more medical products con-
tributes substantially to increased longevity. According to Fogel (1994), the drastic increase in
life expectancy, especially in developing countries (see Table 1), may be due to increased control
by human beings over the environment. Throughout human history and until approximately two
centuries ago, life expectancy was primarily exogenous. More recently, though, it has become the
endogenous outcome of human decision making.
Figure 1 summarizes our hypothesis regarding medical technology diﬀusion. R&D in advanced
countries creates medical technology which diﬀuses to other countries. Diﬀusion is either embodied
9Exeptions include Chakraborty (2004), Ehrlich and Chuma (1990), Grossman (1972), Hall and Jones (2004),
Philipson and Becker (1998), and Usher (1973).International Medical R&D Spillovers 7
in medical imports and/or occurs via the direct transfer of medical knowledge and ideas. R&D
expenditures in advanced countries’ pharmaceutical and other health-related industries serve to
enhance the technology content of speciﬁc medical products, which in due time are also imported
by non-R&D performing countries.
2.1 Economic environment
We set out some simplifying assumptions to make our model tractable and focused on the relation-
ship of interest. Particular attention is paid to constructing a model so that its reduced form can
ultimately be taken to the data by means of empirical estimation. Since our primary interest is in
health status in less advanced economies (the vast majority of which are not involved in medical
R&D), we assume no domestic production of medical products or domestic medical R&D. Domestic
agents take the frontier level of medical technology as given, choosing between imported medical
inputs that will enhance their life expectancy (and their future utility) and consumption goods that
enhance their current utility. This trade-oﬀ between health and consumption goods, and therefore
future vs. present consumption, is the driving force of an otherwise standard neoclassical growth
model.
Without loss of generality, we assume that the economy is populated by a constant number
of identical agents normalized to unity. A representative agent has a ﬁnite life expectancy with
conditional probability qt+1 of being alive at the beginning of period t+1. We assert this probability
depends positively on an agent’s “investment” in health inputs and an exogenously given rate of








, 0 <q<1,B>0,γ∈ (0,1), (1)
where B is an exogenous parameter, Mt is the number of health products at period t, hjt is
the amount of health product j at period t, γ is the share of medical product j in total health
“investment” and vt is the exogenously growing (at rate gv) arrival of illnesses and virus mutations
that reduces the probability of survival.
Equation (1) is a key equation and several points are worth noting. First, consistent with
observation, the probability of being alive next period is a positive function of various exogenous
eﬀects such as genes, habits and culture which we aggregate and represent by parameter B. Second,
the survival probability is negatively related to the arrival of diseases that impact the agent everyInternational Medical R&D Spillovers 8
period. We consider the assumption that the arrival rate of diseases is exogenous to be quite
reasonable. However, we recognize that this variable may vary from country to country, or at
least from region to region, and take account of this in our empirical analysis. Finally and most
importantly, we assert that the survival probability is positively related to investment in medical
inputs.10 Health inputs are incorporated in equation (1) as the sum of all amounts (h)o fm e d i c a l
products (or varieties, M) imported.11
2.1.1 Household problem
Using a recursive structure the household problem can be stated as follows:






















s.t. : wt + rtat = ct +
Mt X
j=1









where {at,w t,M t,p jt}∞
s=t are given. (5)
V (·)i sav a l u ef u n c t i o n ,c is per capita consumption, ρ is the discount factor, w is wage, r is rent,
and pjt is the price of health product j at time t. The representative agent’s utility maximization
problem (in equation 2) diﬀers from standard utility maximization because agents maximize the
sum of their utility function appropriately discounted, conditional on the probability of survival




is qualitatively similar to the O-ring-function suggested by Kremer (1993). Equation (3) is the
representative agent’s budget constraint: it states that income from wages (wt)a n dr e n t s( rtat)i s







asset investment (it = at+1 − at). Aq u a l i ﬁcation is in place here. For simplicity and tractability
10Two clarifying comments are in place here. Throughout the paper we use the terminology “health investment”
rather than “health consumption”. This is to emphasize that consumption of medical goods today has only temporal
(and not instantaneous) utility eﬀects. Also, we use the terminology “medical inputs” rather than “medical goods”
so as to emphasize the fact that one can think of these goods as inputs into a health production function.
11As mentioned, in this study we are only interested in the experiences of countries that are (primarily) medical
goods importers rather than producers. Thus, we do not model medical production that takes place in ten leading
economies (the overwhelming source of medical goods production and R&D) and also exclude these ten countries
from empirical estimation.International Medical R&D Spillovers 9
we assume that when an agent dies, s/he is immediately replaced by a new born that inherits all
assets (at) accumulated by the deceased.12 Equation (4) is the law of motion of the conditional
probability of survival discussed previously.
Optimality implies the following ﬁrst-order conditions:13




























The diﬀerence between equation (8) and the standard neoclassical Euler equation is the appearance
of the probability of survival (q). Put diﬀerently, if we set q = 1 (the neoclassical model assumption),
equation (8) reduces to the standard Euler equation.
2.2 Consumption good production
In our model, the only good that provides utility to consumers is produced with a Cobb-Douglas
intensive production technology that is given by (assuming constant population we set it as nu-




where y is output per capita, k is capital per capita, A is a labor-augmenting productivity parameter
that grows exogenously at rate gA,a n dα is the capital share. Assuming a competitive market, the
wage (w) and rental rate (r)a r eg i v e nb y





where δ is a constant capital depreciation rate.
12This assumption is made for simplicity. With this assumption everyone in the economy is alike in the sense that
they share the same value of the state variable.
13In models with an endogenous discount factor, the optimization problem may not be well-deﬁned and problems
with the second order conditions may arise. This is not a concern here because Stern (2003) has proved the existence
of a solution to an optimization problem such as ours.International Medical R&D Spillovers 10
2.3 Characterization of the aggregate economy
The aggregate economy is characterized by the following system of equations:



























q0,v 0,h 0,k 0,A 0 given. (12)
Equations (S1-S2) are the two ﬁrst-order conditions from the household optimization problem.
Equation (S3) is the survival probability equation, (S4) is the law of motion of capital and (S5)
the aggregate production function. Equation (S6) is the expenditure equation which states that, in
addition to ﬁnal good consumption and investment in physical capital, agents spend part of their
income on medical inputs. Finally, equations (S7-S8) show input prices determined by competitive
conditions.
2.4 Steady-state
Assuming a constant-rate-of-risk-aversion utility function, u(ct)=c1−σ
t /(1 − σ), where σ is the
inverse of the intertemporal elasticity of substitution, the model yields the Euler equation for
consumption goods as
(1 + gA)=[ ρq∗(1 + r∗)]
1/σ , (13)
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and the probability of survival as
q∗ = B (M∗/v∗)h∗γ = B(M∗h∗)γ(M∗)1−γ/v∗, (15)
where (∗) denotes steady state values.14 Equation (15) shows that, in the steady state, the proba-
bility of survival, q∗, is positively related to imports of medical products [(M∗h∗)γ or the product
of medical varieties and their corresponding amounts scaled by parameter γ], a medical R&D exter-
nality [(M∗)1−γ or the number of medical varieties innovated abroad but used domestically scaled
by 1 − γ],15 and a parameter (B)t h a tm a yr e ﬂect exogenous eﬀects of institutions, culture, and
policy. In addition, the probability of survival is negatively related to the arrival rate of viruses, v.
Equation (15) establishes a relationship between health status and medical imports that moti-
vates our empirical analysis. The logarithmic version of (15) yields our baseline testable equation
lnqi = a0 − a1 lnvi + a2 ln(hM)i + a3 lnMi + εi, (16)
where qi (the probability of survival) is captured by health status in country i, vi (the arrival of
diseases) is captured by a country’s geographic proximity to the tropics, (hM)i represents imports
of health products embodying medical technology, Mi represents direct medical R&D spillovers to
the non-frontier country via knowledge ﬂows from frontier countries, and εi is a random error. In
implementing (15) empirically we represent steady-state values of the variables via their empirical
long-run averages and, thus, we have omitted the (∗) superscript in (16). Equation (16) is the
baseline model we estimate after we discuss data construction in the next section.
3D a t a d e s c r i p t i o n
We describe the data set we have assembled to test our main hypotheses and take a ﬁrst look at
the relationship of health with medical imports and foreign medical R&D. The focus of our study,
the probability of survival, is measured by three variables reﬂecting a country’s health status: life
expectancy at birth, the rate of male mortality and the rate of infant mortality.
14A detailed derivation of the Euler and steady-state equations appears in the appendix.
15This externality is common in product variety-based R&D growth models (e.g. Romer (1990)) and is due to the
complementarity among medical inputs. This reﬂects the beneﬁt of spreading a given total of inputs, Mhj,o v e ra
wider range, M. The beneﬁt arises because of diminishing returns to each of the hj individually. The assumption
that γ<1 is necessary for this type of externality to exist. The smaller the value of γ the larger the complementarity
among inputs and the higher the externality.International Medical R&D Spillovers 12
Table 2: Categories of imported medical products used in estimation
Medicinal & Pharmaceutical Products (54) Hyg. & Pharm. Articles of Rubber (6281)
Electric Apparatus for Medical Purposes (774) Orthopaedic Appl., Surg. Belts & the like (8996)
Medical Instruments & Appliances (872) Optical Goods (884)
Medical, Dental, Surg. or Vet. Furniture (82121) Insecticides (5911)
Laboratory, Hyg. & Pharm. Glassware (66581)
Notes: Medicinal and Pharmaceutical Products include, among others, the following sub-categories:
Antibiotics (5413), Antisera and Microbial Vaccines (54164), and Medicaments containing Antibiotics
and derivatives thereof (54171).
We employ three main sources of data. First, the OECD International Trade by Commodity
Statistics (ITCS) database contains medical-related exports (in current $US) from each of the ten
leading innovators of medical technology (Belgium, France, Germany, Italy, Japan, the Netherlands,
Sweden, Switzerland, the U.K., and the U.S.) to each of the importing countries. These ten countries
supply the bulk of medical products and carry out the vast majority of medical R&D. We use this
data set to measure a country’s imports of medical inputs because it is the only consistent source of
medically-related trade. The ITCS database includes annual bilateral ﬂows across 269 international
locations for 2581 goods categories (with a great deal of missing observations) for the period 1960-
2000. We inspected this list of traded goods categories independently, consulting bio-specialists
when in doubt, to come up with a list of thirteen health related traded goods sub-categories. We
excluded four of these categories for which data availability was a serious concern16 and were left
with the nine categories reported in Table 2 (with SITC Revision 2 codes in parentheses). Our
ﬁnal trade dataset contains exports of each of the nine categories from each of the ten “medical
frontier” countries to each of seventy-three “non-frontier” countries.
Initially, we consider an aggregate measure of a country’s medical imports as the sum of all
the pharmaceutical, medical, and health-related categories reported in Table 2. In addition to our
aggregate measure of medical imports we also consider a measure of medical capital and equipment
as the sum of two categories: Electric Apparatus for Medical Purposes (SITC code 774) and Medical
Instruments & Appliances (SITC code 872). Finally, we also consider a third measure of medical
16These categories were: Soap, organic surface-active products and preparations (5541), Sinks, wash basins, bidets,
water closet pans, etc (8122), Disinfectants packed for sale etc. (59141), and Preparations culture media for develop-
ment of micro-organisms (59893).International Medical R&D Spillovers 13
imports: medicinal and pharmaceutical imports alone (SITC code 54). To convert ﬁgures from
current to constant (1990) dollars, we use the manufacturing and chemicals industry price deﬂator
(for each of the ten providers of medical goods) extracted from the 1998 OECD Intersectoral
Database (ISDB 1998).17 Finally, our measure of real medical imports is converted to a per capita
basis by dividing by each recipient’s total population.
Second, to construct our measure of foreign medical innovation and the spillover eﬀe c tw eu s e
the ANBERD 2001 database for pharmaceutical R&D in eight technologically advanced countries
(the ten listed above minus Belgium and Switzerland for which no R&D data exist) from 1973
to 1997. These eight countries account for the vast majority of OECD (and thus global) medical
R&D: they accounted for 96 percent of all medical R&D expenditures reported to the OECD in 1973
and for 94 percent in 1995. The Commission on Macroeconomics and Health (2001, p. 79) notes
the so called 90/10 disequilibrium in medical R&D spending: only 10 percent of R&D spending
is directed at diseases pertinent to 90 percent of the global population. It would seem, ap r i o r i ,
that most R&D spending in the leading economies ought not have an impact on health in non
leading economies. Two points are worth mentioning here. While the disequilibrium may exist so
that most medical R&D is directed at Type I diseases (incident in both rich and poor countries
e.g. measles, hepatitis B, diabetes tobacco-related illnesses) or Type II diseases (incident in both
rich and poor but prevalent in poor, e.g. HIV/AIDS and tuberculosis), such R&D may have an
impact on health in lower income economies, an empirical issue to which our paper is addressed.
Second, the signiﬁcant estimates of medical R&D on health in less advanced economies uncovered
by our empirical estimation (see next section) should be seen as ‘lower bounds’ on the eﬀects of
medical R&D: any reallocation of R&D resources (as urged by the Commission) will likely bring
substantially greater health beneﬁts to non leading economies.
Our R&D expenditures measure is the current PPP dollars series for (SIC Revision 2) category
“Drugs and Medicines” for the eight leading economies.18 We deﬂate these by the chemical industry
price deﬂators from the ISDB database. Finally, we construct a measure of medical R&D ﬂow for
each non-frontier country by multiplying R&D in constant US dollars of each of the eight source
17We use the chemical industry price deﬂator for pharmaceuticals imports and the manufacturing sector price
deﬂator for other types of medical imports.
18R&D spending on other medical products is only available at an aggregate level that includes a broad set of non-
medical categories such as Electric Machinery excluding Communications Equipment, and Professional Goods, which
would be rather imperfect matches for R&D on Electric apparatus for medical purposes and for Medical instruments
and appliances, respectively.International Medical R&D Spillovers 14
countries by the value share of exports of that source country in total medical exports to the









where PHAEXci is pharmaceuticals exports by source country c to destination country i,a n dCRDc
is pharmaceutical R&D expenditures by source country c.19
One potential concern with our imports-weighted R&D measure is that it captures trade-related
eﬀects rather than the disembodied ﬂow of ideas. However, the correlations between PHARD
and the medical imports measures are very low (-0.03 with medical imports, 0.11 with medical
capital and equipment imports, and -0,08 with pharmaceutical imports); it is, thus, unlikely to
capture trade-related eﬀects.20 Moreover, in the empirical analysis we include medical imports as
a separate variable along with PHARD in all estimated models; this helps to isolate the eﬀects of
foreign medical R&D from potential trade-related eﬀects. The fact that both variables appear to
be independently signiﬁcant determinants of health status (see next section), along with the low
correlations between PHARD and the imports measures, suggests that the weights employed to
construct PHARD capture ‘non-trade’ factors (e.g. institutional, cultural, linguistic and physical
proximity between locations) that enhance the ﬂow of ideas from one location to another.
Third, we use a number of health output and health input variables from various sources. The
World Development Indicators (WDI) 2002 database provides data on life expectancy at birth,
infant mortality per thousand live births, male mortality per thousand male adults, physicians
per thousand people, the female illiteracy rate,21 the percentage of population with access to an
improved water source,22 sanitation,23 and hospital beds per thousand people. The WDI also
19In the cross-sectional empirical application of the next section, we use the average of this variable over the period, a
measure closely connected to the level of the medical R&D stock of each country. This foreign R&D measure is similar
in spirit to the one used in the capital-goods technology diﬀusion literature and has little cross-sectional variation. It
varies across diﬀerent importing countries to the degree that one country imports more from a more-R&D intensive
source country rather than a less R&D intensive country.
20In order to create a variable that captures trade-related technology ﬂows, Coe et al. (1997) construct an additional
variable by interacting the imports-weighted R&D variable with a general indicator of openness.
21Deﬁned as the percentage of females ages 15-24 who cannot, with understanding, read and write a short simple
statement on their everyday life.
22Access to an improved water source refers to the percentage of the population with reasonable access to an
adequate amount of water from an improved source, such as a household connection, public stand-pipe, borehole,
protected well or spring, and rainwater collection. Reasonable access is deﬁned as the availability of at least 20 liters
per person a day from a source within one kilometer of the dwelling.
23Deﬁned as the percentage of the population with access to improved sanitation facilities.International Medical R&D Spillovers 15
provides data on total population and GDP per capita in PPP dollars. We also obtained data on
daily calorie intake from the Food Balance Sheets database of the Food and Agriculture Organization
(FAO). We construct total daily calorie intake per person as the sum of calorie intake from both
vegetable and animal sources. Data on each country’s geographic latitude (proximity to the tropics)
is from Hall and Jones (1999). Finally, in robustness checks, we use two broad indicators of
openness: the log of the number of years during which a country is open from Hall and Jones
(1999) and the log of the Frankel and Romer (1999) predicted trade share computed from a gravity
model based only on population and geography.
We were able to put together all the above series for 73 countries (excluding the ten countries
listed previously that are the leading source of pharmaceutical production and R&D) during the
period 1961-1995. However, the great majority of these series are not available annually; in some
cases the data are exceedingly sparse in the time dimension.24 Because the cross-sectional dimension
of the dataset is more complete (with data available in all 73 countries for most variables)25 and,
more importantly, because of the inherent long-run nature of the relation under study, we chose
to explore empirically the cross-sectional dimension of our dataset. We do, however, report panel
results as a robustness check on our cross section results. The aforementioned data limitations did
not allow us to exploit fully the dynamic aspects of the panel.
The cross sectional variables are measured as long-run averages (over the 1961-95 period) of
the available data. Table A1 contains information on the mean value of the main variables by
country. Scatter plots between medical imports and health are in Figure 2. The ﬁrst panel shows
a positive correlation between aggregate medical imports and life expectancy (the correlation co-
eﬃcient is 0.71). The correlation between medical imports and health is robust to the choice of
health indicator: the other two panels show scatter plots between medical imports, on the one
hand, and male and infant mortality rates, on the other (the correlation coeﬃcients are -0.73 and
-0.79, respectively). In the following section we examine systematically the health-medical imports
relationship.
24Life expectancy and infant mortality rates are available about every other year, male mortality rates are available
about once per decade, calorie intake about twice per decade, and physicians about a third of the time. Moreover,
water and sanitation are available about one tenth of the time for most countries, the variable hospital beds is
available about twenty percent of the time, and the two openness variables are available only once per country during
this period.
25One variable for which we have several missing countries in the cross-section is female illiteracy whose availability
is restricted to 62 of the 73 countries in our complete sample.International Medical R&D Spillovers 16
Figure 2: Scatter plots between measures of health and medical imports
Notes: The correlation between medical imports and life expectancy, male mortality and infant
mortality are, 0.71, -0.73 and -0.79, respectively.International Medical R&D Spillovers 17
4 Empirical results
4.1 Preliminary evidence
We measure health status by three indicators: average life expectancy at birth (LIFE), infant mor-
tality (INFANT) and male mortality (MALE). In Table 3 we report the cross sectional unconditional
correlations.26 All variables are in natural logs.
Health status has a strong correlation with our aggregate measure of medical imports (MEDIM)
that includes, pharmaceuticals, imports of medical equipment and other broadly deﬁned medical
imports (all the categories listed in Table 2): the correlation of MEDIM with life expectancy, infant
mortality, and male mortality is 0.71, -0.79, and -0.73, respectively. In addition we consider two
other measures of medical imports, per capita pharmaceutical imports (PHAIM) and (per capita)
imports of medical capital and equipment (MCAPIM): the correlation between PHAIM and the
three health indicators is 0.65, -0.74 and -0.68, respectively, and between MCAPIM and the three
health indicators is even higher (0.83, -0.88 , and -0.83, respectively).
One might argue that, to a large extent, the high correlations between medical imports and
health outcomes are due to the positive eﬀect of per capita income on both variables. For example,
the correlation of GDP per capita with LIFE is 0.77 and with MEDIM is 0.81. In the next section,
we control for this by including the exogenous component of per capita income and we also include
a number of health inputs through which income may determine health outcomes. Table 3 shows
that health inputs, such as calorie intake per person (CAL), the number of physicians per thousand
people (PHYSI), and access to an improved water source (WATER) are also strongly correlated
with life expectancy (correlation coeﬃcients of 0.79, 0.90, 0.79 respectively). We also consider
t h er a t eo ff e m a l ei l l i t e r a c y( ILLIT, correlation with life expectancy = -0.82) and proximity to the
tropics (TROP, correlation with life expectancy = -0.49) and include all these variables as potential
determinants of life expectancy.
Our main hypothesis is that medical imports embody foreign health technologies developed
through R&D in the advanced countries. In addition, a complementary hypothesis is that health
technologies developed in advanced economies diﬀuse to the rest of the world in the form of ideas,
26As mentioned previously, our sample includes 73 countries but excludes the ten countries (Belgium, France,
Germany, Italy, Japan, Netherlands, United Kingdom, United States, Switzerland and Sweden) with a substantial
domestic pharmaceutical sector (eﬀectively, the top ten pharmaceutical exporting nations) in order to focus on health
status in countries that depend on imports of foreign medical technology.International Medical R&D Spillovers 18
Table 3: Unconditional cross-sectional correlations
MEDIM MCAPIM PHAIM PHARD TROP CAL PHYSI ILLIT WATER LIFE INFANT MALE INC
MEDIM 1
MCAPIM 0.95 1
PHAIM 0.99 0.92 1
PHARD -0.03 0.11 -0.08 1
TROP -0.46 -0.51 -0.42 0.02 1
CAL 0.78 0.85 0.74 -0.03 -0.55 1
PHYSI 0.71 0.83 0.65 0.31 -0.59 0.82 1
ILLIT -0.53 -0.70 -0.47 -0.43 0.28 -0.67 -0.71 1
WATER 0.68 0.77 0.64 0.17 -0.48 0.73 0.78 -0.56 1
LIFE 0.71 0.83 0.65 0.31 -0.49 0.79 0.90 -0.82 0.79 1
INFANT -0.79 -0.88 -0.74 -0.10 0.49 -0.85 -0.81 0.89 -0.73 -0.89 1
MALE -0.73 -0.83 -0.68 -0.22 0.56 -0.81 -0.89 0.73 -0.73 -0.94 0.86 1
INC 0.81 0.86 0.77 0.17 -0.53 0.77 0.80 -0.59 0.69 0.77 -0.82 -0.78 1
Notes: All variables are in natural logarithms. The sample size used here is 68 countries, except for ILLIT. MEDIM is aggregate medical imports in constant
$US per person, MCAPIM is imports of medical machinery and equipment in constant $US per person, PHAIM is pharmaceutical imports in constant $US
per person, PHARD is import-country-speciﬁc pharmaceutical -industry R&D in millions of constant dollars implied by R&D of source country multiplied by
import share of that source country in total medical imports from 8 source counries for which R&D data are available, TROP is tropical proximity deﬁned as
the inverse of the absolute value of latitude, CAL is total calories per person, PHYSI is number of physicians per thousand people, ILLIT is illiteracy rate as
a percentage for females ages 15 to 24, WATER is percentage of population with access to improved water source, LIFE is life expectancy, INFANT is infant
mortality, MALE is male mortality and INC is GDP per capita in constant $US.International Medical R&D Spillovers 19
not necessarily embodied in physical imports. In order to evaluate this, we constructed the variable
PHARD (deﬁned in the previous section). The implicit assumption is that a non-R&D performing
country’s health knowledge is implied by the health technology of the countries it trades with (in
the form of medical imports); consequently greater trade intensity with countries that perform large
amounts of medical R&D will increase a country’s health knowledge. The presumption is that the
trade weights used in the construction of PHARD capture physical, cultural, linguistic, and insti-
tutional proximity between countries, all of which would enhance technology ﬂows, independently
of the eﬀect of trade through the embodied technology channel, for which we control separately in
each estimated model (see next section). Table 3 shows that PHARD is also correlated with health
outcomes but less so than the physical imports measures: the correlation with life expectancy is
0.31, and with infant and male mortality -0.10 and -0.22, respectively.
4.2 Cross-section regression results
The correlations in Table 3 provide only suggestive evidence. In this section we control for a
variety of determinants of health status to test systematically the link between imports of health
technology and health status. For example, and as mentioned previously, the positive correlation
between medical imports and health could be due to the positive eﬀect of per capita income on both
variables. Consequently, in the regression model we control for income per capita and also include
a number of health inputs through which income may aﬀect health. To control for per capita
income we include the exogenous component of income per person to account for the endogeneity
between income and health status. We obtain the exogenous component of income as that part
explained in a regression of income per capita on social infrastructure (GADP). Social infrastructure
is the measure assumed by Hall and Jones (1999) to be the main determinant of per capita income
across a wide cross section of economies. GADP is an index of government anti-diversion policies
and measures the role of the government in preventing rent-seeking and other non-wealth creating
activities, as well as the role of government as a possible diverter of private wealth. We believe
that GADP determines per capita income but is, itself, not determined by the health level or,
equivalently, it is exogenous to health status. GADP is a positive and signiﬁcant determinant of
per capita income (estimated coeﬃcient of 2.88 and t-statistic = 8.12) and explains 46 percent of
the variation in per capita income.International Medical R&D Spillovers 20
Our main measure of health is life expectancy; this is the measure used by most studies.27 All
variables are considered in natural logs so our estimates can be interpreted as elasticities. We report
results in the ﬁrst panel of Table 4 with MEDIM as the indicator of medical technology imports. In
addition to the aggregate measure of medical imports, we look at two alternatives: medical capital
and equipment (MCAPIM) in the second panel, and pharmaceutical imports (PHAIM)i nt h et h i r d
panel of Table 4.
We estimate a number of alternative speciﬁcations. All speciﬁcations include the exogenous
component of per capita income to allow for general level of development eﬀects on life expectancy.
Models (1) and (2) include our measures of medical technology diﬀusion. Model (3) is the baseline
regression equation: it tests empirically equation (16) where hM is proxied by medical imports
(MEDIM in panel 1), M is proxied by implied foreign R&D (PHARD), and the arrival of diseases,
v, is approximated by a country’s geographic proximity to the tropics (TROP). The other speciﬁ-
cations (models 4-7) include additional determinants of life expectancy to gauge the robustness of
our estimates.
The results in the ﬁrst panel of Table 4 support the existence of both an embodied medical
technology link via imports of medical products and a disembodied medical technology diﬀusion link
via the direct ﬂow of ideas: the estimate of MEDIM is positive and signiﬁcant in all speciﬁcations
(except model (5) where it is marginally insigniﬁcant, p-value = 0.12), and so is that of PHARD
in models 2-5. The estimate of the elasticity of life expectancy with respect to medical imports is
between 0.012 and 0.056 across the various speciﬁcations: an increase in medical imports by 10
percent results in an increase in life expectancy by between 0.12 and 0.56 percent. While these
elasticities may seem low, we note that a 10 percent increase in per capita income is associated with
an increase in life expectancy of between 0.32 to 1.46 percent. The elasticity of medical imports
is consistently about one third that of per capita income so that a 10 percent increase in income
per capita will have an equivalent impact on life expectancy as a 30 percent increase in medical
imports. While the former increase may be diﬃcult to envisage, at least in the short run, the
second increase is not beyond the bounds of feasible public policy, even in the shorter term.
The elasticity of life expectancy with respect to PHARD ranges from 0.16 for models (2) and
(3) to a (statistically insigniﬁcant) 0.03 in models (6) and (7). We note that this elasticity is
27It should be noted that the correlation between the three indicators of health status is high. While we focus on
life expectancy, we will also discuss the implications of medical imports on the other two indicators of health status
and highlight possible diﬀerences between the three measures.International Medical R&D Spillovers 21
Table 4: Cross-country life expectancy regressions





































































W A T E R–––––– .0172
(0.64)
Adj. R2 58.87 0 .57 1 .57 6 .48 3 .98 6 .28 6 .0
Obs. 72 72 72 70 70 59 59





































































W A T E R–––––– .0068
(0.26)
Adj. R2 68.97 5 .27 5 .57 8 .28 4 .78 6 .88 6 .6
Obs. 73 73 73 71 71 60 60





































































W A T E R –––––– .0108
(0.41)
Adj. R2 56.77 0 .57 1 .57 6 .98 4 .68 6 .88 6 .5
Obs. 73 73 73 71 71 60 60
Notes: * p-value <0.01, ** p-value<0.05, *** p value<0.10, 1p-value = 0.118, 2p-value = 0.165.
Heteroskedasticity-consistent ﬁnite sample standard errors are used in constructing t-statistics.International Medical R&D Spillovers 22
robust across models (2)-(4) but is more than halved once we account for the number of physicians
(PHYSI) in model (5). Greater availability of physicians is one of the main means through which
the ideas channel operates, and including the number of physicians captures in part this channel.
This may account for the reduction in the value of the estimate of PHARD in models (5)-(7).
The exogenous component of per capita income has a positive impact on health in speciﬁcations
(1)-(5). Nevertheless, once we control for calorie intake (CAL) and number of physicians in model
(5), its magnitude falls by half; this suggests that income aﬀects life expectancy in large part via
its impact on calorie consumption and medical care. When we also account for female illiteracy
(ILLIT), the estimated coeﬃcient for income per capita is less than one third of its original value
and becomes statistically insigniﬁcant. Per capita income is probably the most commonly sug-
gested explanation for diﬀerences in health status across countries. Our results suggest that per
capita income level is indeed one of the main determinants of health but the strong eﬀect can be
explained, in large part, once we introduce additional health inputs (such us calorie intake, physi-
cian availability and female education) through which income aﬀects life expectancy. On the other
hand, the signiﬁcant eﬀect of medical imports on life expectancy remains robust even when account
is taken of additional health inputs.
Proximity to the tropics (TROP) has a negative eﬀect on life expectancy in model (3), our base-
line speciﬁcation. In models (4) and (5) we introduce two other health inputs: food consumption28
measured by calorie intake and medical care availability measured by the number of physicians per
thousand people. Both have a strong positive impact on life expectancy: the elasticity estimate of
CAL is the largest among all explanatory variables (0.473 in model 4) but it decreases and becomes
insigniﬁcant once we account for physicians and illiteracy in models (5) and (6). The elasticity with
respect to physicians in model (5) is 0.087 and decreases to 0.063, but remains strongly signiﬁcant,
even after we control for female illiteracy and access to safe water (WATER)i nm o d e l s( 6 )a n d( 7 ) .
In model (6), illiteracy of young women has a signiﬁcant impact on life expectancy with an
estimated elasticity of -0.037. One of the oft-cited propositions in the development literature is
28We recognize that food is of dual usage, i.e. both a consumption and health good. Even though we do not allow
for this in the theoretical model, we allow calorie intake to enter as a regressor in our empirical speciﬁcation of health
status to capture the marginal impact of food consumption on health. This should be positive for countries below
the very top income percentile since over-consumption of food (which can have a negative marginal impact on health
in the richer countries) is less likely to be a problem for the 73 countries studied here. Over-consumption of food
will be relevant for the richer countries, excluded for the most part in this analysis as they also happen to be the top
R&D performers. This non-linearity of the marginal impact of calorie-intake on health is thus left unexplored in the
current study.International Medical R&D Spillovers 23
Table 5: Cross-country male mortality regressions





































































W A T E R–––––– .0649
(0.85)
Adj. R2 58.36 4 .66 9 .77 4 .78 0 .77 5 .97 5 .6
Obs. 70 70 70 68 68 57 57





































































W A T E R–––––– .0845
(1.28)
Adj. R2 68.47 0 .47 4 .07 6 .78 1 .67 7 .17 7 .1
Obs. 71 71 71 69 69 58 58





































































W A T E R–––––– .0657
(0.88)
Adj. R2 56.86 4 .76 9 .97 5 .28 1 .37 6 .87 6 .6
Obs. 71 71 71 69 69 58 58
Notes: * p-value <0.01, ** p-value<0.05, *** p value<0.10, 1p-value = 0.164, 2p-value = 0.157, 3p-value = 0.105,
4p-value = 0.122, 5p-value = 0.107. Heteroskedasticity-consistent ﬁnite sample standard errors are used in constructing t-statistics.International Medical R&D Spillovers 24
the link between female literacy and health; our evidence conﬁr m st h i sp r o p o s i t i o n .W en o t et h a t
when we include ILLIT sample size is reduced by 11 observations. Also the estimated elasticity of
life expectancy with respect to MEDIM is higher (and now statistically signiﬁcant) in model (6).
Interestingly, a comparison of the correlation between imports and health status for this smaller
sample shows that the unconditional correlations are lower in the smaller sample of model (6).29
This suggests that the higher estimate for the impact of imports on health status in model (6) is
not due to sample speciﬁcity but rather due to the inclusion of an important determinant of health
status. Model (6) explains about 86 percent of the cross-sectional variation in life expectancy.
Adding access to an improved water source in model (7) does not alter the magnitude and
signiﬁcance of the coeﬃcient estimates and is, itself, statistically insigniﬁcant. When, however,
we include WATER in a speciﬁcation with only MEDIM and per capita income, its estimated
coeﬃcient (not shown in Table 4) is 0.189 and signiﬁcant. WATER always enters as a signiﬁcant
determinant of health outcomes when included along with medical imports and income. This
suggests that WATER is collinear with other health inputs (the correlation between WATER and
CAL and PHYSICIANS is 0.73 and 0.78, respectively), so that it loses its signiﬁcance when these
are included in the speciﬁcation.30
The results in the second panel of Table 4 for imports of medical capital and equipment
(MCAPIM) are very similar. It is interesting to note that MCAPIM has an even stronger positive
(and statistically signiﬁcant) impact on life expectancy than MEDIM, with elasticity estimates in
the range 0.017-0.081 and statistically signiﬁcant for all models. Moreover, the impact of PHARD
on life expectancy remains positive and signiﬁcant in models 2-5, as before, but its magnitude is
smaller. In models (6) and (7) the estimate of PHARD is statistically insigniﬁcant. If MCAPIM
embodies foreign R&D induced medical technologies to a greater degree than some of the other
import categories included in the more aggregate measure, this should reduce the potential of at-
tributing what is, in eﬀect, embodied technology diﬀusion to direct ﬂo wo fi d e a sa sm e a s u r e db yt h e
29Speciﬁcally, the correlations betwen MEDIM, MEDCAPIM,a n dPHAIM and life expectancy are 0.65, 0.81 and
0.58 for the smaller sample compared to 0.71, 0.83 and 0.65 for the larger sample. Similarly with male mortality
they are -0.64, -0.79 and -0.59 for the smaller sample compared to -0.73, -0.83, -0.68, for the larger sample. Finally,
the correlations with infant mortality are -0.66, -0.80 and -0.59 for the smaller sample compared to -0.79, -0.88, and
-0.74, for the larger sample.
30Another potentially important determinant of life expectancy is sanitation (deﬁned as the percentage of the
population with access to improved sanitation facilities). When we consider sanitation in a speciﬁcation along with
medical imports and income, its estimate is highly signiﬁcant (elasticity is 0.121 and t-statistic = 3.20). However, when
we include additional, potentially collinear, variables the impact of sanitation becomes statistically indistinguishable
from zero with no gain in the adjusted R
2,m u c hl i k eWATER.International Medical R&D Spillovers 25
Table 6: Cross-country infant mortality regressions





































































W A T E R–––––– −.0259
(−.29)
Adj. R2 80.08 2 .28 1 .98 2 .18 3 .68 4 .48 4 .1
Obs. 72 72 72 70 70 59 59





































































W A T E R –––––– .0004
(0.005)
Adj. R2 83.88 4 .28 4 .08 3 .48 4 .38 4 .88 4 .5
Obs. 73 73 73 71 71 60 60





































































W A T E R – – ––– – −.0192
(−0.22)
Adj. R2 79.08 1 .88 1 .68 2 .28 3 .88 4 .78 4 .4
Obs. 73 73 73 71 71 60 60
Notes: * p-value <0.01, ** p-value<0.05, *** p value<0.10. Heteroskedasticity-consistent ﬁnite sample standard errors are used in
constructing t-statistics.International Medical R&D Spillovers 26
R&D stock variable (PHARD). The results are similar, but somewhat weaker, in the third panel of
Table 4 that utilizes pharmaceutical imports alone (PHAIM). Elasticities of life expectancy with
respect to PHAIM range from 0.046 to a (marginally insigniﬁcant) low of 0.01 in model (5). At
t h es a m et i m e ,PHARD now plays a more important role with elasticities ranging from 0.175 to a
(statistically insigniﬁcant) low of 0.039 in models (6) and (7).
The ﬁnding that imports of medical capital and equipment (MCAPIM) have a greater impact
on health status than aggregate medical imports (MEDIM) suggests that our estimates do not
merely capture a broad “trade openness” eﬀect, but instead depend on the degree to which a
given import type embodies R&D-induced technology. This conclusion is reinforced when we add
a general measure of trade openness in the baseline speciﬁcation (model 3). While estimates of
medical imports always retain their economic and statistical signiﬁcance, the estimates of general
trade openness are always smaller than those for medical imports and are never statistically diﬀerent
from zero.31 This conclusion remains unchanged irrespective of health status, openness, or medical
imports measure used.
One potential explanation for the impact of medical imports on health would be that they
serve as a proxy for the status of the domestic health sector. To address this issue, we include a
measure of the number of hospital beds per thousand people as an indication of the status of the
domestic health sector and to isolate the impact of technology ﬂows. This variable is correlated
with MEDIM (correlation coeﬃcient = 0.79) and even more highly correlated with medical capital
and equipment (0.84). When this variable is introduced in the baseline speciﬁcation, its estimate
is highly signiﬁcant (elasticity is 0.075 and t-statistic = 3.07) but becomes statistically indistin-
guishable from zero when we include additional variables. More importantly, the positive impact
of MEDIM (elasticity estimate is 0.029 and t-statistic = 2.09) and PHARD (elasticity estimate is
0.164 and t-statistic = 6.22) remains unaltered, suggesting that our two measures of technology
ﬂows operate independently of this measure of the domestic health sector. The results for the other
two measures of medical imports, MCAPIM and PHAIM, including the hospital beds variable are
31We use the log of the number of years during which a country is open from Hall and Jones (1999) and the log
of the Frankel and Romer (1999) predicted trade share computed from a gravity model based only on population
and geography as general indicators of trade openness. The estimates are not reported in Table 4 but are available,
upon request, and brieﬂy summarized here. Using life expectancy as our measure of health status and MEDIM as
the measure of medical imports, the estimated coeﬃcient for opennness (Hall-Jones measure) is 0.016 (t-statistic =
1.13), while the estimate for MEDIM is 0.039 (t-statistic = 3.85) and for PHARD is .087 (t-statistic = 3.09). When
we use the Frankel-Romer measure, the estimated coeﬃcient for openness becomes -0.005 (t-statistic = -0.18), while
t h ee s t i m a t ef o rMEDIM is 0.052 (t-statistic = 3.04) and for PHARD 0.158 (t-statistic = 5.50).International Medical R&D Spillovers 27
very similar.
In Tables 5 and 6, we explore further the relation between imports of medical technology and
health and measure health status by male mortality rates and infant mortality rates, respectively.
Compared to the estimates for life expectancy, the results for mortality rates present both similar-
ities and some interesting diﬀerences.
The ﬁrst panel of Table 5 shows that the elasticity of male mortality with respect to MEDIM and
PHARD is about twice that of the life expectancy elasticity. The estimates become (marginally)
insigniﬁcant once we control for the number of physicians or female illiteracy. As mentioned pre-
viously, the number of physicians also captures in part the ﬂow of ideas and thus acts to reduce
the estimated impact of PHARD. Proximity to the tropics increases male mortality rates in model
(3), but this eﬀect loses signiﬁcance when the number of physicians or female illiteracy is included.
Calorie intake has a strong negative impact on male mortality rates with an elasticity of -1.192 in
model (4). The elasticity of male mortality rates with respect to physicians, is also relatively high
and robust across models. The (absolute) values of these elasticities are more than twice those for
life expectancy. Illiteracy of young women has no statistically signiﬁcant eﬀe c to nm a l em o r t a l i t y .
We suggest that the main impact of female illiteracy on health is through infant mortality (as will
be discussed presently). Finally, the estimated elasticity of male mortality with respect to income
per person ranges from -0.287 in model (2) to -0.059 and statistically insigniﬁcant in model (6).
In Table 6, we report estimates for infant mortality rates. In model (2) the (absolute) value
of the elasticity of infant mortality rates with respect to MEDIM is about four times the life
expectancy elasticity and about two times the male mortality elasticity. The estimated elasticity of
infant mortality rates with respect to PHARD is -0.31 in models (2)-(4), but becomes insigniﬁcant
once we introduce the number of physicians in model (5). Proximity to the tropics does not seem to
have a signiﬁcant impact on infant mortality rates, and neither does calorie intake. The elasticity
of infant mortality rates with respect to physicians is -0.176. Illiteracy among young women has
as i g n i ﬁcant eﬀect on infant mortality rates and the highest elasticity amongst the explanatory
variables in model (6): a 10 percent increase in female illiteracy is associated with a 2.7 percent
increase in infant mortality. This result provides evidence and reinforces the oft-cited link between
a mother’s education and survival probabilities of infants. Amongst our three health indicators,
increases in per capita income have the largest impact (in terms of elasticity) on infant mortality.
We also note that, while per capita income is signiﬁcant in all models, about 75 percent of itsInternational Medical R&D Spillovers 28
Table 7: Instrumental Variables Estimation for Baseline Speciﬁcation (Model 3)









































































Adj. R2 65.96 6 .66 7 .66 5 .66 4 .46 6 .97 8 .78 0 .07 8 .9
Obs. 64 64 65 62 62 63 64 64 65
Notes: * p-value <0.01, ** p-value<0.05, *** p value<0.10, Heteroskedasticity-consistent ﬁnite sample standard errors are used. The
abbreviation LIF stands for LIFE, MAL for MALE, INF for INFANT, MED for MEDIM, MCAP for MCAPIM, and PHA for PHAIM.
impact goes away as soon as we control for female illiteracy rates.
4.3 Robustness analysis
We consider several variants of our results as robustness checks and also to provide additional
insights into the health-medical technology diﬀusion relationship. First, we explore the possible
endogeneity of medical imports by instrumenting for average medical imports by their initial level.
Second, we consider the robustness of our results to diﬀerent subsamples. Finally, we expand our
data to consider panel estimation in order to take advantage of the time dimension in the data.
4.3.1 Instrumenting for medical imports
We estimate our baseline speciﬁcation instrumenting average medical imports over the 1964-95
period by their predetermined value at the beginning of the period (1961-1963). We consider this
because, in many cases, observations for 1961 (the initial year) are missing. The rationale is that
the average value of medical imports per capita may be endogenous to health outcomes during
the thirty-ﬁve year period. To the extent that future health status cannot cause the initial value
of medical imports, we tackle this issue by using the 1961-63 average value of medical imports as
a predetermined instrument for medical imports during 1964-95. We note that, while the most
common practice for resolving the endogeneity problem has been the instrumental variables (IV)
approach, in cross-country regressions treatment of endogeneity problems is less than satisfactory
because of the lack of a set of viable exogenous instruments.32 Bearing this in mind, in Table
32Durlauf (2001, p.66), among others, argues that studies using IV to address endogeneity are not convincing as
their choice of instruments does not meet the necessary exogeneity requirements.International Medical R&D Spillovers 29
7 we present indicative IV results for our baseline speciﬁcation with the three diﬀerent measures
of health status and three measures of medical imports. In the ﬁrst three columns, we measure
health status with life expectancy, in the following three columns with male mortality rates, and in
the last three columns with infant mortality rates. The results reinforce our previous conclusions
and suggest that real per capita medical imports have a positive causal impact on health status,
irrespective of measure of medical imports or health status.
4.3.2 Endogenous subsample splitting
We follow Hansen’s (2000) methodology that searches for endogenously determined subsamples in
cross-country data in order to explore the possibility of a threshold in the underlying relationship.
Hansen (2000) develops a statistical theory of threshold estimation in the linear regression context
that allows for cross-section observations. The main advantage of Hansen’s methodology over the
regression-tree model (e.g. Durlauf and Johnson (1995)) is that it is based on an asymptotic
distribution theory that can formally test the statistical signiﬁcance of regimes selected by the
data.33
We select model (5) in Tables 4-6 to investigate possible subsample splitting. The reason is
twofold: ﬁrst, it allows for a large number of observations and regressors; and, second, it is generally
the model with the least pronounced eﬀect of medical imports — our key explanatory variable — on
health (see Tables 4-6). In particular, we search for endogenously determined subsamples using the
three proxies for medical imports (MEDIM, MCAPIM, PHAIM) as potential threshold variables.
T h ee n t i r ee x e r c i s ei n v o l v e sn i n ev a r i a t i o n so fm odel (5) (three panels in each of Tables 4-6). To
save space and because the results are qualitatively similar for the three measures of health status,
we present results only with life expectancy as the depended variables (the remaining results are
available from the authors upon request). That is, we consider three variations of model (5), with
life expectancy as the dependent variable, in which MEDIM, MCAPIM, PHAIM are the regressors
(and potential threshold variables), respectively. As an additional robustness check, we have applied
this threshold methodology to model (6); the results are reported in Appendix Table A2.
33For a detailed discussion of the statistical theory for threshold estimation in linear regressions, see Hansen (2000)
and Caner and Hansen (2004).International Medical R&D Spillovers 30
Table 8: List of countries in subsamples













Angola Algeria Angola Algeria Angola Algeria
Argentina Australia Bangladesh Argentina Argentina Australia
Bangladesh Austria Bolivia Australia Bangladesh Austria
Bolivia Canada Cameroon Austria Bolivia Cameroon
Brazil Costa Rica China Brazil Brazil Canada
Cameroon Cote D’Ivoire Cote D’Ivoire Canada Chile Costa Rica
Chile Cyprus Ethiopia Chile China Cote D’Ivoire
China Denmark Ghana Colombia Colombia Cyprus
Colombia Ecuador Haiti Costa Rica Egypt Denmark
Egypt Finland India Cyprus El Salvador Ecuador
El Salvador Greece Indonesia Denmark Ethiopia Finland
Ethiopia Iceland Kenya Ecuador Ghana Greece
Ghana Iran Madagascar Egypt Guatemala Iceland
Guatemala Ireland Malawi El Salvador Haiti Iran
Haiti Israel Mali Finland Honduras Ireland
Honduras Jamaica Mozambique Greece India Israel
India Jordan Myanmar Guatemala Indonesia Jamaica
Indonesia Korea Nigeria Honduras Kenya Jordan
Kenya Mauritius Pakistan Iceland Korea Mauritius
Madagascar New Zealand Philippines Iran Madagascar New Zealand
Malawi Norway Rwanda Ireland Malawi Norway
Malaysia Panama Senegal Israel Malaysia Panama
Mexico Portugal Sierra Leone Jamaica Mali Portugal
Morocco Spain Sri Lanka Jordan Mexico Spain
Mozambique Tunisia Sudan Korea Morocco Tunisia
Myanmar Uruguay Tanzania Malaysia Mozambique Uruguay
Nigeria Venezuela Uganda Mauritius Myanmar Venezuela
Pakistan Zaire Mexico Nigeria
Paraguay Zambia Morocco Pakistan




Sierra Leone Peru Senegal
Sri Lanka Portugal Sierra Leone
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Table 9: Subsample regressions (Model 5)





















































































Adj. R2 70.98 6 .5 53.77 6 .2 73.49 0 .6
Obs. 43 27 30 41 44 27
Notes: Life expectancy is the dependent variable. * p-value <0.01, ** p-value<0.05, *** p value<0.10,
1p-value = 0.170. Heteroskedasticity-consistent ﬁnite sample standard errors are used in constructing t-statistics.
Hansen’s statistical theory allows for one threshold for each threshold variable and we use
the heteroskedasticity-consistent Lagrange Multiplier test developed by Hansen (1996). First, we
consider model (5) with MEDIM as the regressor and potential threshold variable. The bootstrap
Lagrange multiplier test statistic for an endogenous sample split is signiﬁcant (p-value = 0.06),
indicating that there exists a sample split based on MEDIM. The least-squares estimate of the
threshold parameter is 1.79, so that MEDIM divides the sample of 70 countries into a low-imports
group (below 1.79) with 43 countries and a high-imports group (above 1.79) with 27 countries.
Second, we consider MCAPIM as a threshold variable. The bootstrap Lagrange multiplier test
statistic is highly signiﬁcant (p-value = 0.002) and the estimate of the threshold level is -0.72.
MCAPIM splits the sample of 71 countries into two subsamples with 30 countries in the low-
imports group and 41 countries in the high-imports group. Finally, PHAIM is considered as a
threshold variable. The bootstrap Lagrange multiplier test statistic is also signiﬁcant (p-value =
0.039) and the estimate of the threshold level is 1.42. Thus the sample can be split into two
subsamples comprising of 44 countries (above 1.42) and 27 countries (below 1.42). Table 8 presents
the countries in the three pairs of subsamples.
I nT a b l e9 ,w ep r e s e n te s t i m a t e so ft h er e g r e s s i o nc o e ﬃcients of the three variants of modelInternational Medical R&D Spillovers 32
(5) for the two identiﬁed regimes. The estimates for virtually all regressors vary extensively in
magnitude and signiﬁcance in each pair of subsamples. For example, PHARD has a much stronger
impact for countries in the low-imports subgroup. More importantly, the subsample estimates reveal
that the eﬀect of medical imports on life expectancy is particularly pronounced in the subsample
with high medical imports (Subsample 2), whereas in the subsamples with low medical imports
(Subsample 1) the relationship is insigniﬁcant. With MEDIM as a threshold variable, the coeﬃcient
estimate for MEDIM is −0.002 and insigniﬁcant in Subsample 1, and 0.019 and signiﬁcant (10%
level) in Subsample 2. Similarly, with MCAPIM as a threshold variable, the estimate for MCAPIM
is −0.009 and insigniﬁcant in Subsample 1, and 0.046 and highly signiﬁcant (1% level) in Subsample
2. Finally, with PHAIM as a threshold variable, the relevant coeﬃcient estimates are −0.007 and
insigniﬁcant in Subsample 1, and 0.012 and marginally insigniﬁcant (17% level) in Subsample 2. To
conclude, threshold estimation reveals another facet of the relationship between medical imports
and health. It appears that countries have to surpass a threshold level of medical imports before
they can reap the beneﬁts of medical imports in terms of improved health. This conclusion holds
irrespective of model: similar results for model (6) are reported in Appendix Table A2.
4.3.3 Panel estimation
The relation between health status and technological diﬀusion is a long-run one. For this reason,
we have emphasized the cross-sectional dimension of the data. We also constructed a panel dataset
to consider the robustness of the main ﬁndings to the time dimension. We divided our data
sample into four subperiods corresponding to 1961-1969, 1970-1979, 1980-1989 and 1990-1995.
The unconditional correlations for the panel are for the most part strikingly similar to the cross-
sectional correlations in Table 3. For example, the correlations between medical imports and our
three measures of health status are 0.66 (life expectancy), -0.76 (infant mortality), and -0.69 (male
mortality). The same is true for the correlations between the three indicators of health status and
each of our other two measures of imports. A notable exception is the correlation between health
status and PHARD: they are much higher than in the cross section.34 We report the unconditional
panel correlations in Appendix Table A3.
Table 10 contains panel regression results. It includes three panels: one for each of three
34The panel correlations are 0.52, -0.50, and -0.45 for life expectancy, infant mortality, and male mortality respec-
tively, compared to 0.31, -0.10, and -0.22 in the cross-section.International Medical R&D Spillovers 33
Table 10: Panel regressions
.
LIFE/MEDIM LIFE/MCAPIM LIFE/PHAIM















































































Adj. R2 59.47 4 .88 4 .26 7 .27 5 .98 4 .25 7 .37 4 .48 4 .3
Obs. 283 209 153 283 209 153 285 210 154
MALE/MEDIM MALE/MCAPIM MALE/PHAIM















































































Adj. R2 59.77 1 .97 4 .86 6 .97 3 .27 6 .45 7 .57 1 .67 4 .8
Obs. 267 199 144 267 199 144 269 200 145
INFANT/MEDIM INFANT/MCAPIM INFANT/PHAIM















































































Adj. R2 77.68 0 .78 5 .28 1 .88 2 .28 4 .87 5 .87 9 .98 5 .2
Obs. 285 210 154 285 210 154 287 211 155
Notes: * p-value <0.01, ** p-value<0.05, *** p value<0.10. Heteroskedasticity-consistent ﬁnite sample standard errors used.International Medical R&D Spillovers 34
measures of health status. In order to conserve space, we report estimates for each of the three
measures of medical imports for three speciﬁcations that correspond to cross-sectional speciﬁcations
(1), (4) and (7). We consider all health inputs utilized in cross-sectional analysis, with the exception
of tropical proximity because that measure is inherently cross-sectional.35 As previously, in all
models we control for income per capita via the exogenous component of income. We also control
for the presence of global exogenous shocks speciﬁc to each decade by including decade-speciﬁc
dummy variables (not shown in Table 10).
Al o o ka tt h eﬁrst panel of Table 10 shows that the estimated coeﬃcients are very close to those
of the cross sectional estimation. The results support both the ‘embodied’ medical technology
diﬀusion hypothesis and the ‘disembodied’ technology diﬀusion hypothesis: the impact of medical
imports and PHARD on life expectancy is positive and highly signiﬁcant for all three speciﬁcations
(1, 4, and 7) irrespective of measure of medical imports used. Additional health inputs such as
calorie intake, physician availability, and female illiteracy are always signiﬁcant determinants of life
expectancy, as is income per capita. As in the cross-sectional analysis, access to water is insigniﬁcant
when included along with other inputs (but signiﬁcant when included only with medical imports
and PHARD).
The estimates in the second panel of Table 10 for male mortality tell a similar story. The one
exception is speciﬁcation 7, where the estimated coeﬃcients for medical imports and PHARD are
negative but insigniﬁcant. Finally, the estimates for infant mortality rates in the third panel are
supportive of the embodied technology diﬀusion hypothesis: the estimated coeﬃcient for the impact
of medical imports is statistically signiﬁcant for all speciﬁcations irrespective of import measure. On
the other hand, the coeﬃcient estimate for PHARD is consistent with the disembodied technology
diﬀusion hypothesis for speciﬁcation 4 but not for 7. Finally, female education has the largest
impact (in terms of elasticity) on infant mortality and is also highly signiﬁcant.
5C o n c l u s i o n
While much has been written about the beneﬁcial eﬀects of international R&D spillovers from
capital goods technology for both developed and developing economies, there has been no research
on potential beneﬁts from the diﬀusion of medical technology. Our main hypothesis is that medical
35Including it leaves other estimated coeﬃcients virtually unchanged, while TROP itself is usually insigniﬁcant.
Moreover, the adjusted R
2 with TROP included is usually lower.International Medical R&D Spillovers 35
technologies resulting from R&D in advanced economies beneﬁt not only the countries originating
these technologies, but also other nations, in terms of enhanced health status. The extent of these
beneﬁts is captured by direct imports of goods embodying these technologies or in terms of ideas
ﬂowing from the originators of R&D to the rest of the world. Moreover, these beneﬁts depend on
the intensity of medical goods trade by each recipient nation, in the ﬁrst instance, and, second, by
the size of medical R&D expenditures in the source countries with which a recipient trades.
In this paper, we present a simple model of medical technology imports where individuals can
inﬂuence their probability of survival by the amount of spending on imported medical goods. We
test this model for a cross section of 73 economies that are not producers of medical technology or
goods, but instead rely heavily (if not exclusively) on imports of medical technology. In our regres-
sion speciﬁcations we introduce a number of additional health inputs to ascertain the importance
of medical imports, independent of these inputs. Our main message is that imports of medical
goods are a signiﬁcant determinant of health status in non-R&D performing economies. We also
ﬁnd strong evidence for the hypothesis that R&D diﬀuses from the originator nations to recipients
i nad i s e m b o d i e df o r mv i at h eﬂow of ideas. While per capita income is a signiﬁcant determinant
of health status in some speciﬁcations, its importance goes away when additional health inputs
are included. On the other hand the diﬀusion of medical technology is a consistent and signiﬁcant
contributor to health improvements in non-medical frontier economies in all speciﬁcations.
Along with other favorable domestic improvements, medical technology diﬀu s i o ni si nl a r g e
part responsible for the decline in global inequality in life expectancy, especially during the latter
half of the 20th century, as noted in the introduction. In recent years, governmental and non-
governmental bodies have called for additional resources to be devoted to medical R&D, especially
R&D directed at controlling communicable diseases pertinent to poorer nations (Type III diseases),
and have highlighted the health and macroeconomic beneﬁts of such resources (see the Commis-
sion on Macroeconomics and Health, 2001). Our evidence lends support to the beneﬁts that such
R&D investments would have on health outcomes in less advanced economies, as the fruits of such
investments ﬁlter to the rest of the world through the diﬀusion of medical technology.International Medical R&D Spillovers 36
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Appendix
Table A1: Mean Values of Cross Section Data (73 Countries)
Country Code Life Male Infant Med. Med.Cap. Pharm.
Exp. Mort. Mort. Imp. Imp. Imp.
Algeria DZA 4.064 5.541 4.648 2.509 0.290 2.318
Angola AGO 3.691 6.316 5.086 1.151 -1.099 0.918
Argentina ARG 4.231 5.325 3.679 1.729 0.358 1.221
Australia AUS 4.301 5.158 2.569 3.468 2.186 2.862
Austria AUT 4.285 5.249 2.876 4.383 2.767 3.898
Bangladesh BGD 3.871 6.069 4.793 -0.857 -3.130 -1.200
Bolivia BOL 3.930 5.971 4.819 0.879 -0.721 0.455
Brazil BRA 4.116 5.478 4.311 0.891 -0.369 0.301
Cameroon CMR 3.872 6.247 4.711 1.700 -1.152 1.422
Canada CAN 4.315 5.073 2.623 3.676 2.614 2.794
Chile CHL 4.202 5.535 3.679 1.772 0.596 1.058
China CHN 4.145 5.772 4.142 -1.655 -2.548 -2.963
Colombia COL 4.157 5.541 4.003 1.198 -0.204 0.622
Costa Rica CRI 4.253 5.174 3.584 2.552 0.975 1.949
C. d’Ivoire CIV 3.839 6.160 4.795 2.044 -0.931 1.849
Cyprus CYP 4.297 5.036 2.920 3.608 1.583 3.212
Denmark DEN 4.305 5.041 2.408 4.291 2.613 3.800
Ecuador ECU 4.118 5.503 4.380 1.903 0.171 1.447
Egypt EGY 4.010 5.597 4.820 1.438 -0.409 0.815
El Salvador SLV 4.076 5.796 4.448 1.794 -0.019 1.287
Ethiopia ETH 3.723 6.162 5.009 -0.702 -2.616 -1.206
Finland FIN 4.286 5.418 2.192 3.836 2.309 3.387
Ghana GHA 3.953 6.057 4.574 1.078 -1.277 0.796
Greece GRC 4.308 4.970 3.064 3.375 1.507 2.981
Guatemala GTM 4.014 6.036 4.459 1.736 -0.442 1.076
Haiti HTI 3.900 5.971 4.866 0.559 -1.820 0.214
Honduras HND 4.048 5.753 4.424 1.607 -0.364 1.171
Iceland ICE 4.333 4.942 2.285 4.026 2.377 3.587
India IND 3.968 5.721 4.691 -1.688 -2.712 -2.384
Indonesia IDN 3.969 6.068 4.569 -0.519 -2.096 -1.085
Iran IRN 4.044 5.339 4.649 2.041 0.136 1.574
Iraq IRQ 4.059 5.623 4.554 2.179 0.327 1.808
Ireland IRL 4.288 5.113 2.717 4.615 2.856 4.240
Israel ISR 4.290 4.941 2.895 3.573 2.334 2.912
Jamaica JAM 4.247 5.286 3.686 2.115 0.222 1.734
Jordan JOR 4.213 5.322 3.751 2.855 1.109 2.465
Kenya KEN 3.958 6.102 4.466 0.857 -1.439 0.515International Medical R&D Spillovers 39
Table A1: Mean Values of Cross Section Data (73 Countries) cont.
Country Code Life Male Infant Med. Med. Cap. Pharm.
Exp. Mort. Mort. Imp. Imp. Imp.
Korea KOR 4.159 5.761 3.571 1.864 0.894 0.958
Madagascar MDG 3.877 5.937 4.890 0.796 -1.917 0.505
Malawi MWI 3.742 6.168 5.127 -0.475 -2.216 -0.965
Malaysia MYS 4.185 5.659 3.577 1.677 0.243 1.060
Mali MLI 3.710 6.222 5.165 – -1.722 0.305
Mauritius MUS 4.176 5.565 3.699 2.471 0.267 2.060
Mexico MEX 4.177 5.476 4.080 1.551 0.478 0.853
Moroco MAR 4.669 5.701 4.030 1.299 -0.649 0.918
Mozambique MOZ 3.746 6.203 5.071 0.136 -2.376 -0.307
Myanmar MMR 3.920 5.951 4.768 -0.838 -2.988 -1.295
New Zealand NZL 4.291 5.190 2.643 3.418 1.749 3.027
Nigeria NGA 3.808 6.289 4.791 0.796 -1.541 0.485
Norway NOR 4.325 4.998 2.347 4.037 2.516 3.559
Pakistan PAK 3.971 5.764 4.873 0.393 -1.673 -0.097
Panama PAN 4.222 5.319 3.680 4.175 1.597 4.013
Paraguay PRY 4.197 5.343 3.873 1.246 -0.216 0.418
Peru PER 4.066 5.759 4.480 1.330 -0.515 0.958
Philippines PHI 4.101 5.874 4.210 0.624 -1.249 0.210
Portugal PRT 4.259 5.197 3.563 3.151 1.170 2.849
Rwanda RWA 3.773 6.236 4.909 -0.033 -1.726 -0.401
Senegal SEN 3.789 6.357 4.781 1.658 -1.015 1.420
Sierra Leone SLE 3.544 6.345 5.274 0.731 -1.626 0.476
Singapore SGP 4.257 5.387 2.699 4.198 2.866 3.286
Spain ESP 4.310 5.069 2.966 2.958 1.541 2.395
Sri Lanka LKA 4.197 5.292 3.644 0.238 -1.712 -0.222
Sudan SDN 3.840 6.289 4.837 1.179 -2.054 0.379
Tanzania TZA 3.856 6.221 4.796 0.207 -2.213 -0.196
Thailand THA 4.124 5.712 4.048 1.157 -0.451 0.653
Tunisia TUN 4.124 5.543 4.383 2.433 0.351 2.198
Turkey TUR 4.093 – 4.656 1.231 -0.145 0.564
Uganda UGA 3.862 6.207 4.726 -0.265 -2.214 -0.734
Uruguay URY 4.252 5.197 3.575 2.079 0.460 1.606
Venezuela VEN 4.206 5.429 3.753 2.315 0.965 1.773
Zaire ZAR 3.856 – 4.777 -0.485 -2.858 -0.726
Zambia ZMB 3.858 6.249 4.680 1.016 -0.844 0.656
Zimbabwe ZWE 3.954 6.072 4.394 0.473 -1.092 -0.083
Notes: All variables are in logarithms. The sources are the World Development Indicators (WDI), and the OECD
International Trade by Commodity (ITCS) databases. Summary statistics for the remainder of the data used in this
paper are available from the authors.International Medical R&D Spillovers 40
Table A2: Subsample regressions (Model 6)

































































































Adj. R2 83.38 0 .6 84.57 7 .1 91.48 6 .5
Obs. 37 22 27 33 21 39
Notes: Life expectancy is the dependent variable. * p-value <0.01, ** p-value<0.05, *** p value<0.10.
Heteroskedasticity-consistent ﬁnite sample standard errors are used in constructing t-statistics.International Medical R&D Spillovers 41
Table A3: Unconditional panel correlations
MEDIM MCAPIM PHAIM PHARD TROP CAL PHYSI ILLIT WATER LIFE INFANT MALE INC
MEDIM 1
MCAPIM 0.94 1
PHAIM 0.99 0.89 1
PHARD 0.12 0.36 0.06 1
TROP -0.43 -0.46 -0.40 -0.05 1
CAL 0.73 0.80 0.68 0.19 -0.51 1
PHYSI 0.67 0.79 0.61 0.49 -0.55 0.76 1
ILLIT -0.56 -0.72 -0.49 -0.47 0.27 -0.63 -0.72 1
WATER 0.59 0.70 0.56 0.46 -0.42 0.64 0.69 -0.54 1
LIFE 0.66 0.80 0.59 0.52 -0.46 0.77 0.88 -0.80 0.72 1
INFANT -0.76 -0.87 -0.70 -0.50 0.45 -0.81 -0.81 0.89 -0.68 -0.88 1
MALE -0.69 -0.80 -0.63 -0.45 0.53 -0.77 -0.88 0.73 -0.69 -0.92 0.85 1
INC 0.59 0.66 0.56 0.05 -0.44 0.71 0.64 -0.59 0.69 0.66 -0.75 -0.64 1
Notes: All variables are in natural logarithms. Complete data is available for 68 countries (except for ILLIT) and four sub-periods: 1961-1969, 1970-1979,
1980-1989 and 1990-1995. For the deﬁnition of variables see Table 3.International Medical R&D Spillovers 42
Derivation of Euler equations and steady-state conditions
Rewrite the household maximization problem substituting the state variables qt+1 and at+1




























The ﬁrst order conditions (FOCs) are
∂V (at)
∂ct








∂hjt . In addition,
V 0 (at)=ρqt+1V 0(at+1)(1 + rt). (A4)
Combining (A2) and (A4) and iterating one period ahead yields equation (6) in the text:
u0(ct)=ρqt+1(1 + rt+1)u0(ct+1). (18)







ρV (at+1)=pjt u0(ct). (19)
Using the recursive structure of V (at), we can rewrite the optimization problem as
V (at+1)=u(ct+1)+ρqt+2V (at+2), (A5)


























Equation (8) can be rewritten after substituting for the values of q and q0 as









Next, we discuss the determination of prices pjt. Given no production of new medical technolo-
gies in the domestic economy (we assume the countries of interest only import medical goods) the
price is exogenously given and can be normalized to unity. Alternatively, we can add more structureInternational Medical R&D Spillovers 43
to the model by assuming that innovating ﬁrms abroad operate under monopolistic competition
and choose monopoly prices, pjt,a c c o r d i n gt ot h ep r o ﬁt maximization problem
max
hjt
πjt = pjthjt − hjt, (A8)
where, for simplicity, it is assumed that health goods are produced with the same production






















Taking the ﬁrst derivative of pjt with respect to hjt, multiplying by
hjt





= γ − 1. (A12)
Substituting (A12) into (A10) gives








Next, we assert that the steady state assumption, gv = g∗
M = gA, is an assumption necessary for
the existence of a balanced growth and one that secures that the probability of survival q is constant
in steady state: this is the only logical assumption because q can not possibly grow indeﬁnitely. To
see why this assumption is important, consider the law of motion of q g i v e ni ne q u a t i o n( 4 )w h i c h ,







Dividing by qt and using the fact that, at the steady state, g∗














q =0( i . e .q is a constant) only when gv = g∗
M.
36The steady-state growth conditions are derived by applying standard growth accounting methodology to equations
(S3-S8).International Medical R&D Spillovers 44
Finally, we derive the steady-state level equations (13-15 in the text). Using the FOC (6) and




= ρqt+1(1 + rt+1)
1+gc = ρqt+1(1 + rt+1), (A16)
which at the steady state yields equation (13).
























and rearranging gives equation (14) in the text.
Finally, using equation (1) with the symmetry condition we readily obtain steady-state equation
(15) in the text.